

IN THE CLAIMS

1. (Currently Amended) A method for modulating a transplantation-associated immune response, comprising:

administering to a subject in need of an effective amount of ~~The use of~~ a conjugate comprising a carboxyl group-containing organic compound and albumin,
wherein said carboxyl group-containing organic compound is a cytostatic or an immunosuppressant ~~for producing a pharmaceutical for modulating a transplantation-associated immune response, the conjugate being obtainable by reacting the carboxyl group-containing organic compound and albumin in the presence of 1-ethyl-3-(3-dimethylaminopropyl) carbonyldiimide as activating reagent.~~

2. (Canceled)

3. (Currently Amended) The method of use as claimed in claim 1, wherein said transplantation-associated immune response is for producing a pharmaceutical for the prophylaxis or/and treatment of GVHD (graft versus host disease[])(GVHD).

4. (Currently Amended) The method of use as claimed in claim 3, wherein said ~~characterized in that~~ GVHD is an acute GVHD.

5. (Currently Amended) The method of use as claimed in claim 3, wherein said ~~characterized in that~~ GVHD is a chronic GVHD.

6. (Currently Amended) The method of use as claimed in claim 1, wherein said ~~characterized in that the~~ transplantation is a bone marrow transplantation.

7. (Currently Amended) The method of use as claimed in claim 1, wherein said ~~characterized in that the~~ transplantation is an organ transplantation, ~~in particular a kidney, heart or liver transplantation.~~

8. (Currently Amended) The method of use as claimed in claim 1, wherein said
~~characterized in that the~~ transplantation is an allogeneic transplantation.
9. (Canceled)
10. (Currently Amended) The method of use as claimed in claim 1, wherein said
~~characterized in that the~~ carboxyl group-containing organic compound is selected from the group
consisting of methotrexate, [[or]] aminopterin and [[or]] N-phthaloyl-L-glutamic acid.
11. (Canceled)
12. (Currently Amended) The method of use as claimed in claim 1, wherein said
~~characterized in that the~~ albumin is human albumin.
13. (Currently Amended) The method of use as claimed in claim 1, wherein said
~~characterized in that the~~ albumin is a native human albumin.
14. (Currently Amended) The method of use as claimed in claim 1, wherein said
~~characterized in that the~~ conjugate is a methotrexate-albumin conjugate.
15. (Currently Amended) A method for preparing a conjugate comprising [[i)]]a
 carboxyl group-containing organic compound and [[ii)]]albumin, said method comprising:
activating said carboxyl group-containing organic compound with 1-ethyl-3-(3-
dimethylaminopropyl) carbonyldiimide in an organic solvent; and
reacting activated carboxyl group-containing organic compound with albumin,
wherein said carboxyl group-containing organic compound is a cytostatic or an
immunosuppressant ~~characterized in that a carboxyl group-containing organic compound and~~
~~albumin are reacted in the presence of 1-ethyl-3-(3-dimethylaminopropyl) carbonyldiimide as~~
~~activating reagent.~~

16. (Canceled)

17. (Currently Amended) The method ~~of as claimed in~~ claim 15, wherein said ~~characterized in that the~~ carboxyl group-containing organic compound is selected from the group consisting of methotrexate, aminopterin and ~~and~~ [[/or]] N-phthaloyl-L-glutamic acid.

18. (Currently Amended) The method ~~of as claimed in~~ claim 17, wherein said ~~characterized in that the~~ carboxyl group-containing organic compound is methotrexate.

19. (Currently Amended) The method ~~of as claimed in~~ claim 18, ~~characterized in that~~ the wherein said methotrexate is reacted with albumin at a methotrexate:albumin carboxyl group-containing organic compound:albumin molar ratio of ~~is from~~ 10:1 to 1:10, ~~in particular~~ 1.5:1 to 1:1.5.

20. (Currently Amended) The method ~~of as claimed in~~ claim 15, wherein said ~~characterized in that the~~ carboxyl group-containing organic compound is activated ~~reacted in an~~ organic solvent, ~~in particular in an anhydrous organic solvent~~, with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide in an anhydrous organic solvent by heating, ~~is activated by heating and then the activated carboxyl group-containing organic compound is reacted with the~~ protein.

21. (New) The method of claim 8, wherein said organ transplantation is selected from the group consisting of kidney, heart and liver transplantation.

22. (New) The method of claim 18, wherein said methotrexate is reacted with albumin at a methotrexate:albumin molar ratio of 1.5:1 to 1:1.5.